Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust
Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust
Cambridge, United Kingdom5 results · Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Long-term Efficacy and Safety Extension (LTE) Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria | Chronic Disease, Chronic Spontaneous Urticaria, Disease Attributes, Hypersensitivity, Immediate, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Skin and Connective Tissue Diseases, chronic urticaria, immune system disorder, skin disorder, skin vascular disease, urticaria | Enrolling by invitation | Phase 3 | 2026-10-07 | NCT07256392 | |
| Phase 3 Study of Pelabresib (CPI-0610) in Myelofibrosis (MF) (MANIFEST-2) | Hemic and Lymphatic Diseases, Myeloproliferative Disorders, bone marrow disorder, hematologic disorder, primary myelofibrosis | Active, not recruiting | Phase 3 | 2026-07-17 | NCT04603495 | |
| ARISTOCRAT: Blinded Trial of Temozolomide +/- Cannabinoids | Brain Tumor, Recurrent, Chemically-Induced Disorders, Disease Attributes, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Recurrence, astrocytoma (excluding glioblastoma), brain disorder, cannabis dependence, central nervous system cancer, central nervous system disorder, epithelial neoplasm, glioblastoma, glioma, neoplasm, nervous system disorder, neuroepithelial neoplasm, primitive neuroectodermal tumor, psychiatric disorder, substance-related disorder | Recruiting | Phase 2 | 2026-05-05 | NCT05629702 | |
| Tessa Jowell BRAIN MATRIX - Platform Study | Neoplasms by Histologic Type, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, epithelial neoplasm, glioma, neoplasm, neuroepithelial neoplasm, primitive neuroectodermal tumor | Recruiting | Not stated | 2026-05-05 | NCT04274283 | |
| Impact of Apalutamide in Metastatic Hormone Sensitive Prostate Cancer Patients | Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) | Active, not recruiting | Not stated | 2025-09-18 | NCT06019676 |